Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation who are at risk of stroke. Results are due in 2020.

Advertisement

Related Content

Xarelto Filing Puts It Out Ahead In Venous Thromboembolism
Xarelto Tested FDA’s Comparative Efficacy Powers, But Conservative View Prevailed
Janssen Looks To Differentiate Anticoagulant Xarelto With Broad Label
Eliquis Delay Fuels Speculation About Advisory Committee Meeting
Pradaxa Bleeding Deaths Spur FDA Concerns, European Label Changes
Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?
FDA Approval Of Xarelto Bodes Well For Drug’s Future Expansion
Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005086

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel